OSOBENNOSTI TEChENIYa YaZVENNOGO KOLITA NA FONE TERAPII INFLIKSIMABOM
- Авторлар: Shapina M.V1, Khalif I.L1, Golovenko A.O1, Kashnikov V.N1
-
Мекемелер:
- Шығарылым: № 15 (2015)
- Беттер: 40-43
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288186
- ID: 288186
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
This retrospective study was aimed to the assessment of further course of the disease in patients with ulcerative colitis (UC), who initially had response to infliximab induction course and had relapses occurred against the background of maintenance therapy. There were 46 patients treated with infliximab during the year. Therapy was administered in the case of hormone dependence or hormone resistance. In the case of relapse, dose optimization before next administration was recommended. In the case of mild-to-moderate activity of relapse, therapeutic dose of 5-acetylsalicylic acid was prescribed to patients before the next administration. In severe attack and high activity, systemic corticosteroids were administered, and surgical treatment was considered. The study identified four types of course of UC on background of anticytokine therapy, depending on the frequency and timing of relapses. However, further observation of a large number of patients to clarify the frequency of occurrence of these types and their application in clinical practice is required.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М., 2008. 400 с.
- Клинические рекомендации по диагностике и лечению взрослых больных язвенным колитом, 2013. 22 с.
- Van Limbergen J., Russell R.K., Nimmo E.R., Ho G.T., Arnott I.D., Wilson D.C., Satsangi J. Genetics of the innate immune response in inflammatory bowel disease. Inflamm. Bowel Dis. 2007; 13: 338-55.
- Ko Y., Butcher R., Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World J. Gastroenterol. 2014; 7; 20(5): 1238-47.
- Speight R.A., Mansfield J.C. Drug advances in inflammatory bowel disease. Clin. Med. 2013; 13: 378-82.
- Sales-Campos H., Basso P.J., Alves V.B., Fonseca M.T.C., Bonfa G., Nardini V., Cardoso C.R.B. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz. J. Med. Biol. Res. 2014; 28.
- Rutgeerts P., Sandborn W.J., Feagan B.G.R., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med 2005; 353: 2462-76.
- Arora Z., Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep. (Oxf). 2014; 24.
- Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2013; 5(23): 65-73.
- Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol. 2011; 106(4): 685-98.
- Lawrance I.C. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J. Gastroenterol. 2014; 7; 20(5): 1248-58.
- Probert C.S.J., Hearing S.D., Schreiber S., Kühbacher T., Ghosh S., Arnott I.D., Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52: 998-1002.
- Bermejo F., Lopez-Sanroman A., Hinojosa J., Castro L., Jurado C., Gomez-Beldal A.B. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig. 2004; 96: 94-101.
- Armuzzi A., De Pascalis B., Lupascu A., Fedeli P., Leo D., Mentella M.C., Vincenti F., Melina D., Gasbarrini G., Pola P., Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci. 2004; 8(5): 231-33.
- Halpin S.J., Hamlin P.J., Greer D.P., Warren L., Ford A.C. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J. Gastroenterol. 2013; 21; 19(7): 1091-97.
- Ochsenkühn T., Sackmann M., Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol. 2004; 16: 1167-71.
- Allez M., Karmiris K., Louis E., Van Assche G., Ben-Horin S., Klein A., Van der Woude J., Baert F., Eliakim R., Katsanos K., Brynskov J., Steinwurz F., Danese S., Vermeire S., Teillaud J.L., Lemann M., Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohn's Colitis. 2010; 4: 355-66.
- Ben-Horin S., Chowers Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 2011; 33: 987-95.
- Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 2014; 13(1): 24-30.
- Ordas I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 2012; 91(4): 635-46.
Қосымша файлдар
